PharmaTher Holdings Ltd.
PHRRF
Rank in Stocks
#31374
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm,... PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Share Price
$0.0409
Last synced: 2026-11-09
Market Cap
$3.22M
Change (1 day)
2.00%
Change (1 year)
-52.44%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade PharmaTher Holdings Ltd. (PHRRF)
Category
Healthcare
EPS for PharmaTher Holdings Ltd. (PHRRF)
EPS as of August 2026 TTM: $0.00
According to PharmaTher Holdings Ltd.'s latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of $-0.01, an increase over its 2024 EPS of $-0.03.
EPS history for PharmaTher Holdings Ltd. from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -70.00% |
| 2025 | $-0.01 | -51.74% |
| 2024 | $-0.03 | -51.77% |
| 2023 | $-0.05 | 37.34% |
| 2022 | $-0.04 | -214.33% |
| 2021 | $0.03 | -17,200.00% |
| 2020 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -522,100.00% |
US
|
|
| $-7.07 | 235,566.67% |
US
|
|
| $-5.29 | 176,233.33% |
AU
|
|
| $12.88 | -429,436.67% |
BE
|
|
| $21.56 | -718,766.67% |
NL
|
Questions about PharmaTher Holdings Ltd.'s earnings per share (EPS)
What is PharmaTher Holdings Ltd.'s earnings per share (EPS)?
PharmaTher Holdings Ltd.'s earnings per share (EPS) over the last twelve months is $0.00, as of Aug 2026.
What was PharmaTher Holdings Ltd.'s earnings per share (EPS) in 2025?
In 2025, PharmaTher Holdings Ltd.'s earnings per share (EPS) was $-0.01, compared with $-0.03 in 2024.
How has PharmaTher Holdings Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, PharmaTher Holdings Ltd.'s earnings per share (EPS) was highest in 2021 ($0.03) and lowest in 2023 ($-0.05).
How does PharmaTher Holdings Ltd.'s earnings per share (EPS) compare with similar companies?
PharmaTher Holdings Ltd.'s earnings per share (EPS) ($0.00) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.